American journal of cancer research最新文献

筛选
英文 中文
Machine learning-based quantitative pathology reveals intratumoral heterogeneity in ductal carcinoma in situ and predicts invasive upstaging. 基于机器学习的定量病理学揭示了原位导管癌的肿瘤内异质性,并预测了浸润性晚期。
IF 3.1 3区 医学
American journal of cancer research Pub Date : 2026-09-25 eCollection Date: 2026-01-01 DOI: 10.62347/SZJY1956
Libo Yang, Jie Chen, Chuanfen Lei, Miao Yang, Pengzhou Cai, Jing Fu, Ting Yin, Peilu Gao, Hongyu Wang, Zhiwei Tan, Chen Shu, Li Li, Fei Chen, Leyi Gao, Junsheng Lin, Yuhao Yi, Zhang Zhang
{"title":"Machine learning-based quantitative pathology reveals intratumoral heterogeneity in ductal carcinoma <i>in situ</i> and predicts invasive upstaging.","authors":"Libo Yang, Jie Chen, Chuanfen Lei, Miao Yang, Pengzhou Cai, Jing Fu, Ting Yin, Peilu Gao, Hongyu Wang, Zhiwei Tan, Chen Shu, Li Li, Fei Chen, Leyi Gao, Junsheng Lin, Yuhao Yi, Zhang Zhang","doi":"10.62347/SZJY1956","DOIUrl":"10.62347/SZJY1956","url":null,"abstract":"<p><p>This study aimed to develop a machine learning framework for objective ductal carcinoma in situ (DCIS) grading and to investigate intratumoral heterogeneity as a predictive biomarker. The grading framework was developed using 267 DCIS resections and validated on two external test sets (n=116 and n=69). A single-cell grading model graded individual nuclei using quantitative measures of nuclear size and pleomorphism. An integrated grading model then combined single-cell with architectural features in a support vector machine classifier. Separately, an invasion prediction model was trained on 288 intermediate- and high-grade DCIS cases and validated on 54 cases to predict upstaging to invasive carcinoma >1 mm. Compared to low-grade nuclei, high-grade nuclei were significantly larger and less uniformly oriented (all P<0.001). The single-cell grading model achieved F1 scores of 0.76, 0.62, and 0.80 for low-, intermediate-, and high-grade nuclei, respectively. In one external test set, the integrated grading model achieved F1 scores of 0.83, 0.71, and 0.72 for low-, intermediate-, and high-grade DCIS, respectively. On 54 intermediate- and high-grade DCIS biopsy cases, combining clinical variables with quantitative heterogeneity metrics improved the prediction of upstaging to invasive carcinoma >1 mm over the clinical-only model, increasing the area under the receiver operating characteristic curve from 0.704 to 0.827. These findings identify quantitatively measured intratumoral heterogeneity as a biologically relevant feature that may explain diagnostic ambiguity in borderline cases and help predict extensive invasive upstaging.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"16 9","pages":"4102-4114"},"PeriodicalIF":3.1,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Chinese herbal compound SanHuang decoction reverses axitinib resistance in ccRCC through regulating immune cell infiltration by affecting ADAMTS18 expression. 更正:复方三黄汤通过影响ADAMTS18表达调节免疫细胞浸润逆转ccRCC的阿西替尼耐药。
IF 3.1 3区 医学
American journal of cancer research Pub Date : 2026-09-25 eCollection Date: 2026-01-01 DOI: 10.62347/PXCH9987
Ben Xu, Jiaen Zhang, Lin Ye, Changwei Yuan
{"title":"Erratum: Chinese herbal compound SanHuang decoction reverses axitinib resistance in ccRCC through regulating immune cell infiltration by affecting ADAMTS18 expression.","authors":"Ben Xu, Jiaen Zhang, Lin Ye, Changwei Yuan","doi":"10.62347/PXCH9987","DOIUrl":"https://doi.org/10.62347/PXCH9987","url":null,"abstract":"<p><p>[This corrects the article on p. 2841 in vol. 13, PMID: 37560000.].</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"16 9","pages":"4213-4215"},"PeriodicalIF":3.1,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: CYP19A1 is downregulated by BRD4 and suppresses castration-resistant prostate cancer cell invasion and proliferation by decreasing AR expression. 勘误:CYP19A1被BRD4下调,通过降低AR表达抑制去势抵抗性前列腺癌细胞的侵袭和增殖。
IF 3.1 3区 医学
American journal of cancer research Pub Date : 2026-09-25 eCollection Date: 2026-01-01 DOI: 10.62347/VGMJ2050
Xi Chen, Haopeng Li, Chengdang Xu, Xin'an Wang, Gang Wu, Chao Li, Denglong Wu
{"title":"Erratum: CYP19A1 is downregulated by BRD4 and suppresses castration-resistant prostate cancer cell invasion and proliferation by decreasing AR expression.","authors":"Xi Chen, Haopeng Li, Chengdang Xu, Xin'an Wang, Gang Wu, Chao Li, Denglong Wu","doi":"10.62347/VGMJ2050","DOIUrl":"https://doi.org/10.62347/VGMJ2050","url":null,"abstract":"<p><p>[This corrects the article on p. 4003 in vol. 13, PMID: 37818065.].</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"16 9","pages":"4216-4217"},"PeriodicalIF":3.1,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683319/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
mTOR inhibitor everolimus versus conventional chemotherapy in pediatric low-grade gliomas. mTOR抑制剂依维莫司与常规化疗治疗小儿低级别胶质瘤的比较。
IF 3.1 3区 医学
American journal of cancer research Pub Date : 2026-09-25 eCollection Date: 2026-01-01 DOI: 10.62347/ELZY2242
Chenhao Wei, Xiuying Zhang
{"title":"mTOR inhibitor everolimus versus conventional chemotherapy in pediatric low-grade gliomas.","authors":"Chenhao Wei, Xiuying Zhang","doi":"10.62347/ELZY2242","DOIUrl":"10.62347/ELZY2242","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Standard chemotherapy in pediatric low-grade gliomas (pLGG) has limited efficacy and substantial toxicity, while clinical data on everolimus are lacking. This study compared the efficacy of everolimus and traditional chemotherapy in patients with pLGG, and evaluated the treatment response, survival, and the frequency and severity of adverse events. This single-center retrospective cohort study analyzed 279 patients with pathologically confirmed World Health Organization (WHO) grade 1-2 pLGG (Jan 2014-Jan 2021): 126 received everolimus and 153 received standard carboplatin-vincristine (CV) chemotherapy. The primary efficacy endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and clinical benefit rate (CBR). In the optic pathway glioma subgroup, visual function changes were assessed using the pediatric eye questionnaire (PedEyeQ) scale along with objective ophthalmic indicators including best-corrected visual acuity, visual field assessment, and optic nerve atrophy grading. Safety was evaluated by recording adverse events according to the CTCAE v5.0 criteria, with exposure-adjusted rates calculated per 100 patient-years to account for differential treatment duration, and long-term pediatric safety was assessed through 5-year follow-up of growth, bone metabolism, and endocrine function. The follow-up period was 5 years. The median PFS was 49.00 months (95% CI: 37.00-55.00) in the everolimus group and 41.00 months (95% CI: 28.00-55.00) in the CV group, with no significant difference (Log-rank χ&lt;sup&gt;2&lt;/sup&gt;=0.162, P=0.688) and a hazard ratio (HR) of 0.939 (95% CI: 0.684-1.288). OS did not differ significantly between the everolimus and CV groups (Log-rank χ&lt;sup&gt;2&lt;/sup&gt;=0.423, P=0.515), with an HR of 0.778 (95% CI: 0.365-1.662). No significant differences were observed in ORR, DCR, or CBR (all P&gt;0.05). In the optic pathway glioma subgroup, the 5-year PedEyeQ scores were significantly higher in the everolimus group than in the CV group (P&lt;0.001), and objective ophthalmic assessments consistently demonstrated better visual preservation with everolimus. In terms of safety, the incidence of grade 3-4 adverse events was significantly lower in the everolimus group than in the CV group (22.22% vs. 44.44%, P&lt;0.001). The incidence of hematologic toxicity (26.19% vs. 52.94%, P&lt;0.001) was significantly lower in the everolimus group; non-hematologic toxicities, including nausea, vomiting, and alopecia, were also significantly lower in the everolimus group. The most common adverse events in the everolimus group were oral mucositis (49.21%), hyperlipidemia (38.10%), and rash (25.40%), most of which were grade 1-2 and manageable. Exposure-adjusted safety analyses confirmed these findings, and 5-year follow-up showed no significant between-group differences in growth, bone metabolism, or endocrine function. For pLGG patients, everolimus is comparable to carbo","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"16 9","pages":"4189-4207"},"PeriodicalIF":3.1,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum total bile acid correlates with macrophage-related immune features in colorectal cancer patients after cholecystectomy. 结直肠癌胆囊切除术后血清总胆汁酸与巨噬细胞相关免疫特征的相关性
IF 3.1 3区 医学
American journal of cancer research Pub Date : 2026-09-25 eCollection Date: 2026-01-01 DOI: 10.62347/XXQI9504
Wenjie Kong, Weidong Liu, Lin Yu, Man Wang, Huiwen Jia, Zhiyuan Wang, Feng Gao
{"title":"Serum total bile acid correlates with macrophage-related immune features in colorectal cancer patients after cholecystectomy.","authors":"Wenjie Kong, Weidong Liu, Lin Yu, Man Wang, Huiwen Jia, Zhiyuan Wang, Feng Gao","doi":"10.62347/XXQI9504","DOIUrl":"10.62347/XXQI9504","url":null,"abstract":"<p><p>Cholecystectomy has been associated with an elevated risk of colorectal cancer (CRC), potentially mediated by alterations in bile acid metabolism. This single-center retrospective case-control study aimed to investigate the clinical significance of serum total bile acid (TBA) levels in patients with CRC after cholecystectomy, their association with farnesoid X receptor (FXR) expression, and their relationship with tumour-associated macrophage (TAM)-related immune features within the tumour microenvironment. A total of 216 post-cholecystectomy patients with CRC and 209 post-cholecystectomy controls without CRC were enrolled in the study. Serum TBA levels were quantified and statistically compared between the two groups. Immunohistochemical analysis was performed on tumour tissues to assess FXR expression and TAM markers (CD163, CD68). Pearson correlation analysis was performed to examine the associations among serum TBA levels, FXR expression, and TAM-related immune features. Serum TBA levels were significantly higher in the CRC group (8.74 ± 4.45 µmol/L) compared to the Control group (4.61 ± 2.90 µmol/L). ROC analysis showed an AUC of 0.79 (95% CI: 0.74-0.83). Elevated TBA levels were associated with advanced disease features, including higher TNM stage and lymph node metastasis. Immunohistochemistry revealed increased FXR expression and a higher proportion of CD163<sup>+</sup> TAMs in the high TBA group, while the proportion of CD68<sup>+</sup> TAMs was reduced. Pearson correlation analysis showed that TBA levels were positively correlated with FXR<sup>+</sup> cells (r=0.57, P < 0.001) and CD163<sup>+</sup> macrophages (r=0.51, P < 0.001), and negatively correlated with CD68<sup>+</sup> macrophages (r=-0.44, P < 0.001). Elevated serum TBA levels were associated with increased FXR expression and altered TAM characteristics in CRC after cholecystectomy. These findings indicate that TBA levels may represent a biomarker associated with CRC-related clinicopathological and immune characteristics.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"16 9","pages":"4129-4139"},"PeriodicalIF":3.1,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Genome-wide target interactome profiling reveals a novel EEF1A1 epigenetic pathway for oncogenic lncRNA MALAT1 in breast cancer. 勘误:全基因组目标相互作用组分析揭示了乳腺癌中致癌lncRNA MALAT1的一种新的EEF1A1表观遗传途径。
IF 3.1 3区 医学
American journal of cancer research Pub Date : 2026-09-25 eCollection Date: 2026-01-01 DOI: 10.62347/YTTC6888
Xueli Li, Naifei Chen, Lei Zhou, Cong Wang, Xue Wen, Lin Jia, Jiuwei Cui, Andrew R Hoffman, Jifan Hu, Wei Li
{"title":"Erratum: Genome-wide target interactome profiling reveals a novel <i>EEF1A1</i> epigenetic pathway for oncogenic lncRNA <i>MALAT1</i> in breast cancer.","authors":"Xueli Li, Naifei Chen, Lei Zhou, Cong Wang, Xue Wen, Lin Jia, Jiuwei Cui, Andrew R Hoffman, Jifan Hu, Wei Li","doi":"10.62347/YTTC6888","DOIUrl":"https://doi.org/10.62347/YTTC6888","url":null,"abstract":"<p><p>[This corrects the article on p. 714 in vol. 9, PMID: 31105998.].</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"16 9","pages":"4208-4210"},"PeriodicalIF":3.1,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulsatilla decoction attenuates colorectal cancer progression in association with gut microbiota remodeling, T-cell immune restoration, and NF-κB/JAK2/STAT3 signaling suppression. 白杨汤与肠道菌群重塑、t细胞免疫恢复和NF-κB/JAK2/STAT3信号抑制有关,可减缓结直肠癌的进展。
IF 3.1 3区 医学
American journal of cancer research Pub Date : 2026-09-25 eCollection Date: 2026-01-01 DOI: 10.62347/CPKL9308
Yanghua Jie, Xiaobei Yang, Pengwei Lou, Weidong Chen
{"title":"Pulsatilla decoction attenuates colorectal cancer progression in association with gut microbiota remodeling, T-cell immune restoration, and NF-κB/JAK2/STAT3 signaling suppression.","authors":"Yanghua Jie, Xiaobei Yang, Pengwei Lou, Weidong Chen","doi":"10.62347/CPKL9308","DOIUrl":"10.62347/CPKL9308","url":null,"abstract":"<p><p>Pulsatilla Decoction (PD) exhibits anti-inflammatory properties, but its impact on colorectal cancer (CRC) and the role of gut microbiota remain incompletely understood. This study investigated the antitumor effects of PD in a xenograft mouse model of HCT116 cells reconstituted with human peripheral blood mononuclear cells. We also analyzed corresponding changes in gut microbiota, T-cell immunity, inflammatory responses, and NF-κB/JAK2/STAT3 signaling. Tumor-bearing mice were treated for three weeks with low-, medium-, or high-dose PD, or with 5-fluorouracil. Gut microbiota composition and function were analyzed using 16S rRNA and metagenomic sequencing. Immune cell populations, cytokines, and pathway-related proteins were assessed via flow cytometry, immunofluorescence, ELISA, RT-qPCR, and western blotting. To further evaluate the involvement of microbiota, we performed antibiotic pretreatment followed by fecal microbiota transplantation (FMT). PD effectively reduced tumor volume and weight without causing significant body weight loss. High-dose PD partially restored microbial diversity and community structure, increased Akkermansia muciniphila, and modulated inflammation- and metabolism-related microbial pathways. Furthermore, PD enhanced peripheral and intratumoral CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses, improved the splenic Treg/Th17 balance, decreased TNF-α, IL-6, and IL-17A, increased IL-10, and suppressed NF-κB, JAK2, and STAT3 activation in tumor tissues. FMT from high-dose PD-treated donors partially transferred tumor inhibition, increased tumor CD8A and granzyme B, reduced Foxp3, and lowered NF-κB, JAK2, and STAT3 levels in recipient mice not directly treated with PD. These findings suggest that PD inhibits CRC progression by coordinately modulating gut microbiota, T-cell immunity, inflammation, and NF-κB/JAK2/STAT3 signaling, with the gut microbiota partially contributing to its antitumor effects.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"16 9","pages":"4170-4188"},"PeriodicalIF":3.1,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MKRN2 promotes gastric cancer progression by suppressing autophagy via the PI3K/Akt/mTOR signaling pathway. MKRN2通过PI3K/Akt/mTOR信号通路抑制自噬,促进胃癌进展。
IF 3.1 3区 医学
American journal of cancer research Pub Date : 2026-09-25 eCollection Date: 2026-01-01 DOI: 10.62347/VCYR1308
Miao Wang, Nan Hou, Honglei Wang, Xuqing Ding, Xinchao Sun, Junjie Tu
{"title":"MKRN2 promotes gastric cancer progression by suppressing autophagy via the PI3K/Akt/mTOR signaling pathway.","authors":"Miao Wang, Nan Hou, Honglei Wang, Xuqing Ding, Xinchao Sun, Junjie Tu","doi":"10.62347/VCYR1308","DOIUrl":"10.62347/VCYR1308","url":null,"abstract":"<p><p>Makorin ring finger protein 2 (MKRN2) is associated with the development of various tumors; however, few studies have investigated the role MKRN2 in gastric cancer (GC). This study aimed to investigate the expression and underlying mechanism of MKRN2 in GC. Quantitative real-time PCR (qRT-PCR) and western blotting were adopted to detect MKRN2 expression in GC cells. Cell viability, colony formation, and apoptosis were determined using cell counting kit-8 (CCK-8) assay, colony formation assay, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, respectively. Cell invasion and migration were evaluated using transwell and scratch healing assays. Flow cytometry and immunofluorescence were performed to evaluate M1/M2 macrophage phenotypes. Western blotting was adopted to measure the expression of autophagy-related proteins and components of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. An <i>in vivo</i> xenograft mouse model was established by subcutaneous injection of MKN-45 cells. The expression Ki-67 and MKRN2 in GC tissues was detected by immunohistochemistry (IHC). MKRN2 expression was elevated in GC. MKRN2 overexpression promoted cell proliferation, migration and invasion, whereas MKRN2 knockdown inhibited those cellular behaviors. MKRN2 knockdown increased LC3-II/LC3-I ratio and Beclin1 expression, and decreased p62 level, whereas MKRN2 overexpression produced the opposite effects. Treatment with 3-methyladenine (3-MA) partly reversed autophagy-related changes in GC cells induced by MKRN2 knockdown. On contrary, rapamycin (RAPA) treatment counteracted the inhibition of autophagy caused by MKRN2 overexpression. MKRN2 knockdown reduced xenograft tumor growth in mice. Moreover, MKRN2 knockdown inhibited the phosphorylation and activation of the PI3K/Akt/mTOR pathway. MKRN2 knockdown inhibited M2 macrophage polarization and promoted M1 macrophage polarization. MKRN2 may partook in the pathogenesis and development of GC as an oncogene. These findings laid a foundation for the development of targeted therapy in GC progression.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"16 9","pages":"4152-4169"},"PeriodicalIF":3.1,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Timing of spontaneous hepatocellular carcinoma rupture as a prognostic indicator. 自发性肝癌破裂时间作为预后指标。
IF 3.1 3区 医学
American journal of cancer research Pub Date : 2026-09-25 eCollection Date: 2026-01-01 DOI: 10.62347/RUYW1962
Chin-Wei Chang, Wei-Fan Hsu, Long-Bin Jeng, Hsueh-Chou Lai, Shih-Chao Hsu, Te-Hung Chen, Hung-Wei Wang, Chien-Hung Lin, Ying-Chun Lin, Sheng-Hsien Chen, Yu-Wei Chang, Yu-Min Liao, Cheng-Yuan Peng
{"title":"Timing of spontaneous hepatocellular carcinoma rupture as a prognostic indicator.","authors":"Chin-Wei Chang, Wei-Fan Hsu, Long-Bin Jeng, Hsueh-Chou Lai, Shih-Chao Hsu, Te-Hung Chen, Hung-Wei Wang, Chien-Hung Lin, Ying-Chun Lin, Sheng-Hsien Chen, Yu-Wei Chang, Yu-Min Liao, Cheng-Yuan Peng","doi":"10.62347/RUYW1962","DOIUrl":"10.62347/RUYW1962","url":null,"abstract":"<p><p>The prognostic value of spontaneous ruptured hepatocellular carcinoma (rHCC) and its interaction with Barcelona Clinic Liver Cancer (BCLC) stages remain unclear. To assess the prognostic effects of rHCC and its interaction with BCLC staging. This was a retrospective cohort study enrolled 2,577 patients with hepatocellular carcinoma. rHCC was diagnosed using computed tomographic evidence of capsular disruption with extravasation of blood and classified as early or late according to whether rupture occurred ≤ 7 days or > 7 days after HCC diagnosis, respectively. Propensity score matching (PSM) was used to adjust for confounders. Cox proportional hazards regression models and Kaplan-Meier survival analyses were used to assess the prognostic effects of rHCC across BCLC stages. Of 2,577 patients, 102 (4.0%) had rHCC. Patients with rHCC were younger and had higher BCLC stages, worse liver function, and higher α-fetoprotein levels than those without rHCC. Multivariable Cox regression analysis revealed that late rHCC was a predictor of worse overall survival (OS; hazard ratio [HR]: 1.578, 95% confidence interval [CI]: 1.059-2.351) and that early rHCC was a protective factor (HR: 0.717, 95% CI: 0.519-0.992). A combination of early and late rupture did not predict OS. Kaplan-Meier analysis after PSM revealed that the OS for patients with early rHCC at BCLC stage B or C was similar to that for patients without rHCC (P = .594 for stage B and P = .566 for stage C) and that OS for patients with late rHCC at BCLC stage B or C was significantly worse than that for patients without rHCC (P = .007 for stage B and P = .006 for stage C). Late rHCC is associated with worse outcomes than early rHCC or nonruptured HCC at BCLC stages B and C.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"16 9","pages":"4140-4151"},"PeriodicalIF":3.1,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NCCRP1 promotes ovarian cancer progression and is associated with activation of the PI3K/AKT/mTOR signaling pathway and altered mitochondrial respiration. NCCRP1促进卵巢癌进展,并与PI3K/AKT/mTOR信号通路的激活和线粒体呼吸的改变有关。
IF 3.1 3区 医学
American journal of cancer research Pub Date : 2026-09-25 eCollection Date: 2026-01-01 DOI: 10.62347/OXEM5735
Junhao Jiang, Xuedong Fan, Zhipeng Wang, Man Gao, Ning Zhang, Yang Liu, Rumeng Wang, Kong Qiao, Lizhou Jia
{"title":"NCCRP1 promotes ovarian cancer progression and is associated with activation of the PI3K/AKT/mTOR signaling pathway and altered mitochondrial respiration.","authors":"Junhao Jiang, Xuedong Fan, Zhipeng Wang, Man Gao, Ning Zhang, Yang Liu, Rumeng Wang, Kong Qiao, Lizhou Jia","doi":"10.62347/OXEM5735","DOIUrl":"10.62347/OXEM5735","url":null,"abstract":"<p><p>Non-specific cytotoxic cell receptor protein 1 (NCCRP1) is a membrane protein involved in cell proliferation, but its role in ovarian cancer (OC) progression remains unclear. In this study, a prognostic model for OC was constructed using LASSO-penalized Cox regression analysis. NCCRP1 expression in ovarian tissues was detected by immunohistochemical staining, and its associations with clinicopathological features and prognosis were analyzed. The effects and underlying mechanism of NCCRP1 on the malignant biological behaviors of OC cells were further investigated in vitro and in vivo. The prognostic model consisted of 28 genes with significant prognostic value. Among these genes, NCCRP1 mRNA showed differential expression in ovarian tissues and potential prognostic significance. NCCRP1 protein was overexpressed in OC tissues compared with adjacent ovarian tissues, and high NCCRP1 expression was associated with ascites, tumor cells in ascites, lymph node metastasis, distant metastasis and advanced FIGO stage. Patients with high NCCRP1 expression tended to have poorer overall survival. Knockdown of NCCRP1 inhibited the proliferation, migration and invasion of OC cells and promoted apoptosis, whereas NCCRP1 overexpression produced the opposite effects. In addition, NCCRP1 knockdown decreased oxygen consumption rate, whereas NCCRP1 overexpression produced the opposite effect. NCCRP1 expression was also positively associated with the phosphorylation levels of PI3K, AKT and mTOR. These findings suggest that NCCRP1 promotes malignant biological behaviors in OC, is associated with altered mitochondrial respiratory activity and may exert its tumor-promoting effects, at least in part, through activation of the PI3K/AKT/mTOR signaling pathway. Therefore, NCCRP1 may serve as a novel prognostic marker and potential therapeutic target for OC patients.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"16 9","pages":"4115-4128"},"PeriodicalIF":3.1,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13683320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书